The CAR-T cell therapy market is estimated to be worth USD 14 billion in 2030, predicts Roots Analysis
Given their ability
to selectively direct a cell mediated immune response against cancer cells and,
thereby, offer prolonged periods of disease remission, several CAR-T cell
therapies are expected to achieve blockbuster status
Roots Analysis is pleased to
announce the publication of its recent study, titled, “CAR-T Cell Therapies Market (3rd
Edition) by Target Indications (NHL, Multiple Myeloma, Chronic Lymphocytic
Leukemia, Acute Lymphoblastic Leukemia, Follicular Lymphoma, Mantle Cell
Lymphoma, Hepatocellular Carcinoma and Others), Target Antigens (CD19, BCMA,
CD19 / CD22, GPC3 and EGFR), Key Players and Key Geographies (North America,
Europe, Asia Pacific, Latin America, Middle East and North Africa, and Rest of
the World) – Industry Trends and Global Forecasts, 2021-2030”
The features an extensive study of the current
market landscape and the future potential of CAR-T cell therapies. The report
highlights the efforts of both industry players and academic organizations in
this rapidly evolving segment of the biopharmaceutical industry. Amongst other
elements, the report features the following:
§
A detailed assessment
of the current market landscape of drug developers engaged in the development
of CAR-T cell therapies.
§
Detailed profiles of
marketed and mid-to late stage clinical products (shortlisted on the basis
of the stage of development).
§
An analysis of the
CAR constructs of clinical-stage CAR-T therapies based on the generation of
CAR-T therapy.
§
An analysis
highlighting the key opinion leaders (KOLs) in this domain. It features a 2×2
matrix assessing the relative experience of KOLs shortlisted based on their
contributions (in terms of involvement in various clinical studies) to
this field.
§
An analysis of the
various CAR-T cell therapy focused clinical trials registered across the world,
between 2009 and 2019.
§
An overview of the
various focus therapeutic areas of therapy developers, including an assessment
of the opportunity (in terms of revenue generation potential from therapy
sales) across oncological and non-oncological disease indications.
§ A detailed discussion
on innovative technology platforms that are being used for the development of
CAR-T cell therapies.
§
An analysis of the partnerships that have been established
in the recent past.
§
An analysis of the investments that have been made into
companies that have proprietary CAR-T cell based products / technologies.
§
A case study on other T-cell based therapies, apart from
CAR-Ts, including a detailed analysis of approved / pipeline products.
§
A case study on manufacturing cell therapy products,
highlighting the key challenges, and a detailed list of contract service
providers and in-house manufacturers involved in this space.
§
An elaborate discussion on various factors that form the
basis for the pricing of cell-based therapies.
§
An analysis of the prevalent and emerging trends in this
domain, as represented on the social media platform, Twitter.
§
A review of the key promotional strategies that have been
adopted by the developers of the marketed CAR-Tcell therapies.
§ A detailed market
forecast, featuring analysis of the current and projected future opportunity
across key market segments (listed below)
§ To order this
795+ page report, which features 165+ figures and 270+ tables, please visit https://www.rootsanalysis.com/reports/view_document/car-t-therapies-market/269.html
- Type
of target disease Indication
- Non-Hodgkin’s
lymphoma
- Multiple myeloma
- Melanoma
- Chronic lymphocytic leukemia
§ Acute
lymphoblastic leukemia
§ Follicular
lymphoma
§
Mantle cell lymphoma
- Hepatocellular carcinoma
§
Colorectal cancer
§ Type
of Target Antigens
- CD19
- BCMA
- CD19, CD22
- GPC3
- EGFR
§ Key
Geographical Regions
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and North Africa
- Rest of the World
§ Transcripts of
interviews held with the following senior level representatives of stakeholder
companies
- Tim
Oldham (Chief Executive Officer, cell therapies)
- Troels
Jordansen (Chief Executive Officer, Glycostem Therapeutics)
- Wei
(William) Cao (Co-Founder, Chairman and Chief Executive Officer, Gracell
Biotechnologies)
- Miguel
Forte (Chief Operating Officer, TxCell)
- Adrian
Bot (Vice President, Scientific Affairs, Kite Pharma)
- Vincent
Brichard (Vice President, Immuno-Oncology, Celyad)
- Brian
Dattilo (Manager of Business Development, Waisman Biomanufacturing)
- Aino
Kalervo (Competitive Intelligence Manager, Strategy & Business
Development, Theravectys)
- Xian-Bao
Zhan (Professor of Medicine and Director, Department of Oncology, Changhai
Hospital)
- Enkhtsetseg
Purev (Assistant Professor of Medicine, University of Colorado)
§
To
request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/269/request-sample.html
Key companies covered
in the report
- Autolus
- bluebird
bio
- CARsgen
Therapeutics
§
Celgene (A Bristol
Myers Squibb Company)
- Cellectis
- Cellular
Biomedicine Group
- Innovative
Cellular Therapeutics
- Iovance
Biotherapeutics
- Kite
Pharma (A Gilead Sciences Company)
- Kuur
Therapeutics
- Lion
TCR
- Noile-Immune
Biotech
- Novartis
- Shanghai
GeneChem
- Sinobioway
Cell Therapy
- Takara
Bio
- Ziopharm
Oncology
For
more information please click on the following link:
https://www.rootsanalysis.com/reports/view_document/car-t-therapies-market/269.html
Other Recent Offerings
1. Global T-Cell (CAR-T,
TCR, and TIL) Therapy Market (5th Edition), 2021 – 2030
2. mRNA Therapeutics and
Vaccines Market, 2020-2030
3. Gene Therapy Market
(4th Edition): Industry Trends and Global Forecasts, 2020-2030
About Roots Analysis
Roots Analysis is one of the fastest
growing market research companies, sharing fresh and independent perspectives
in the bio-pharmaceutical industry. The in-depth research, analysis and
insights are driven by an experienced leadership team which has gained many
years of significant experience in this sector. If you’d like help with your
growing business needs, get in touch at info@rootsanalysis.com
Contact Information
Roots Analysis Private
Limited
Gaurav Chaudhary
+1 (415) 800 3415
Facebook - https://www.facebook.com/RootsAnalysis
LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
Twitter - https://twitter.com/RootsAnalysis
Comments
Post a Comment